TITLE

EOPHARM BEGINS TRIAL OF IL13-PE38 FOR MALIGNANT GLIOMA

PUB. DATE
October 2002
SOURCE
Worldwide Biotech;Oct2002, Vol. 14 Issue 10, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Highlights progress on the clinical development program of NeoPharm Inc. for IL13-PE38, a novel tumor-targeted agent.
ACCESSION #
7464134

 

Related Articles

  • NeoPharm's cancer compound could be a potential Taxol rival.  // PharmaWatch: Cancer;December2004, Vol. 3 Issue 12, p5 

    Reports on the results of NeoPharm Inc.'s phase I clinical trials which found the safety and tolerability of the NeoLipid compound, LEP-ETU, in patients with advanced female cancers. Consideration of LEP-ETU as NeoPharm's liposomal formulation of paclitaxel, a chemotherapeutic drug in wide use...

  • NeoPharm reaches agreement with FDA on phase III "Precise" trial.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p20 

    Reports that NeoPharm Inc. reached an agreement with the Food and Drug Administration regarding its Precise trial designed to be a study of the company's experimental tumor-targeting, anticancer drug IL13-PE38QQR, that is being investigated as a treatment for first recurrence of glioblastoma...

  • IU cancer center studies ImClone drug. Maurer, Katie // Indianapolis Business Journal;7/14/2003, Vol. 24 Issue 18, p43 

    Reports on the clinical trials of the anticancer drug Erbitux.

  • Sch-66336 (Sarasar�) and Other Benzocycloheptapyridyl Farnesyl Protein Transferase Inhibitors: Discovery, Biology and Clinical Observations. A.G. Taveras; P. Kirschmeier; C.M. Baum // Current Topics in Medicinal Chemistry;Jun2003, Vol. 3 Issue 10, p1103 

    Farnesyl Protein Transferase as a target for therapeutic intervention is currently under investigation in human clinical trials. Sch-66336 (sarasar�), a benzocycloheptapyridyl Farnesyl Transferase Inhibitor (FTI), has been found to be effective in cellular proliferation assays and in in...

  • Trial Watch.  // Nature Reviews Cancer;Jul2002, Vol. 2 Issue 7, p482 

    Presents findings of clinical trials of candidate antineoplastic drugs recent as of July 2002. Pharmacokinetics and pharmacodynamics of the modified adenoviral vector INGN-241 in patients with advanced carcinoma; Phase I clinical trial of a novel molecule designed to inhibit signaling by the...

  • Clinical trial design changing as molecular targets gain popularity. Hollon, Tom; Hollon, T // JNCI: Journal of the National Cancer Institute;12/5/2001, Vol. 93 Issue 23, p1770 

    Investigates the clinical trial designs for drugs with cytotoxic properties. Identification of cell growth; Observation of solid tumor; Formation of the monoclonal antibody.

  • 1133. A Phase I Study of Antitumor Vaccination Using Genetically Modified Tumor Cells Expressing α(1,3)Galactosyltransferase in Patients with Refractory or Recurrent Non-Small Cell Lung Cancer (NSCLC): Preliminary Results Morris, John C.; Janik, John E.; Vahanian, Nicholas; Moses, Leslie; O'Hagan, Diana; Tennant, Lucinda; Pittaluga, Stefania; Gao, Wendy; Albert, Paul; Seregina, Tatiana; Link, Charles J. // Molecular Therapy;Jun2005, Vol. 11, p437 

    An abstract of the article "A Phase I Study of Antitumor Vaccination Using Genetically Modified Tumor Cells Expressing α(1,3)Galactosyltransferase in Patients with Refractory or Recurrent Non-Small Cell Lung Cancer (NSCLC): Preliminary Results," by John C. Morris and colleagues is presented.

  • NeoPharm: more promising survival data for cintredekin besudotox.  // PharmaWatch: Cancer;Jun2006, Vol. 5 Issue 6, p11 

    The article reports on NeoPharm's release of update phase I/II data for cintredekin besudotox that shows increased survival in glioblastoma multiforme patients. The drug is a chimeric interleukin-13 conjugated to a genetically engineered Pseudomonas exotoxin. The phase III trial was initiated in...

  • NeoPharm: more promising survival data for cintredekin besudotox.  // PharmaWatch: Biotechnology;Jun2006, Vol. 5 Issue 6, p5 

    The article reports on NeoPharm Inc.'s release of the results of phase I/II clinical trial of hts cintredekin besudotox. The updated data showed that the overall median survival of the 45 patients with glioblastoma multiforme (GBM) was 44 weeks. Long-term follow-up demonstrated 22 patients with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics